Tonix Pharm Holdings (TNXP) Stock Price, Quote & News

Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for...

Industry: Biotechnology

Sector: Healthcare

Phone: 862 799 8599

Fax: 862 904 8163

Website: www.tonixpharma.com

Address:

26 Main Street, Suite 101, Chatham, United States

Rungreen Jan. 17 at 1:26 PM

$TNXP This a Phase 3 trial for AXSM product—-NEW YORK, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced the first patient has been dosed in the FORWARD Phase 3 trial of AXS-14 (esreboxetine) for the management of fibromyalgia.

0 · Reply

Ab_23 Jan. 17 at 8:21 AM

$TNXP please tell me there are any good news or numbers

0 · Reply

MoneyGroupLLC Jan. 17 at 7:36 AM

Enter: $TNXP Calls Strike Price: $18 Expiry Date: FEB 20 2026 Buy in Price: $2.13 - $2.60 Sell Price: $4.13 Profit : +94% (Turn every $1 into $1.94) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

WarpedHitbox Jan. 17 at 2:52 AM

^@CoralSharkie operating on another level 🧠❄️ Cold vision, real substance. Not following yet? That’s on you. Free game, unreal value. 🐐 > Also watching >> $TNXP $GOVX $IXHL $USAR .

0 · Reply

Biostock Jan. 17 at 2:32 AM

$TNXP When $25.6 billion per share? The epitome of utter capital destruction.

1 · Reply

SouljaOfYah Jan. 17 at 2:18 AM

$TNXP only a fool would think of selling what they have now…. Patience pays

0 · Reply

crazysnake Jan. 17 at 1:56 AM

$TNXP

0 · Reply

Moemazon Jan. 17 at 1:47 AM

$TNXP imagine if any of those crazy targets from before August 15, 2025 actually come to fruition this year.

0 · Reply

crazysnake Jan. 16 at 11:34 PM

$TNXP looks like we are all too poor to subscribe to iqvia ,bloomberg terminal lol who got those numbers?

0 · Reply

C4Trading Jan. 16 at 10:01 PM

$TNXP Long weekend, should be interesting on Tuesday.

1 · Reply

Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026

Dec 29, 2025, 7:57 AM EST - 19 days ago

Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering

Dec 29, 2025, 7:45 AM EST - 19 days ago

Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Dec 16, 2025, 7:00 AM EST - 4 weeks ago

Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University

Dec 9, 2025, 7:00 AM EST - 5 weeks ago

Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel

Nov 24, 2025, 3:35 PM EST - 7 weeks ago

Tonix: Maintaining Buy Rating With Potential Tonmya Expansion Indications

Nov 24, 2025, 7:00 AM EST - 7 weeks ago

Tonix Pharmaceuticals Announces FDA IND Clearance for Phase 2 Study of TNX-102 SL for the Treatment of Major Depressive Disorder

Nov 17, 2025, 7:00 AM EST - 2 months ago

Tonix Pharmaceuticals Announces U.S. Commercial Availability of TONMYA™ (cyclobenzaprine HCl sublingual tablets) as a First-in-Class Fibromyalgia Treatment

Nov 14, 2025, 9:41 AM EST - 2 months ago

Tonix Q3 2025 Earnings Recap And Tonmya Launch Outlook

Nov 10, 2025, 4:15 PM EST - 2 months ago

Tonix Pharmaceuticals Reports Third Quarter 2025 Financial Results and Operational Highlights

Nov 6, 2025, 7:00 AM EST - 2 months ago

Tonix Pharmaceuticals to Participate in the Stifel 2025 Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 2 months ago

Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Advance Phase 2 Clinical Trial of Dimeric Fc-modified anti-CD40L mAb, TNX-1500, to Prevent Kidney Transplant Organ Rejection

Oct 28, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Announces Presentation at BIO-Europe 2025

Oct 27, 2025, 7:00 AM EDT - 2 months ago

Tonix Pharmaceuticals Presented Data on Tonmya™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2025 American College of Rheumatology (ACR) Convergence

Oct 22, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix's Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital

Oct 21, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals to Present Poster on Tonmya™ at the 2025 American College of Rheumatology (ACR) Convergence

Oct 17, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Presented Data on TNX-801 Mpox Vaccine at World Vaccine Congress–Europe 2025

Oct 14, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Presented an Update on Fc-modified anti-CD40L mAb, TNX-1500, at the 61st Annual Congress of the Japan Society for Transplantation

Oct 9, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025

Sep 30, 2025, 8:30 AM EDT - 3 months ago

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access

Sep 29, 2025, 7:00 AM EDT - 3 months ago

Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026

Sep 18, 2025, 8:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces Positive Pre-IND Meeting with FDA for TNX-102 SL for the Treatment of Major Depressive Disorder

Sep 17, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Announces In-licensing Phase 2/3-Ready Monoclonal Antibody Designed for Seasonal Prevention of Lyme Disease (TNX-4800)

Sep 8, 2025, 7:00 AM EDT - 4 months ago

Tonix Pharmaceuticals Presents Clinical Data on Tonmya™ for the Treatment of Fibromyalgia at PAINWEEK 2025

Aug 28, 2025, 7:00 AM EDT - 5 months ago

Tonix Pharmaceuticals to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2025

Aug 19, 2025, 12:28 PM EDT - 5 months ago

Tonix Pharmaceuticals Soars, Then Sinks: What's Next After Tonmya's Approval (Upgrade)

Aug 16, 2025, 8:45 AM EDT - 5 months ago

Tonix Secures Fibromyalgia Approval - What Investors Should Know

Aug 15, 2025, 3:50 PM EDT - 5 months ago

US FDA approves Tonix Pharma's drug to manage pain related to chronic condition

Aug 15, 2025, 3:44 PM EDT - 5 months ago

Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

Aug 11, 2025, 4:15 PM EDT - 5 months ago

Tonix Pharmaceuticals Reports Second Quarter 2025 Financial Results and Operational Highlights

Jul 21, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces the Launch of the “Move Fibro Forward” Campaign to Bring Awareness to Individuals Impacted by Fibromyalgia

Jul 10, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Presentation of New Data on Mpox and Smallpox Vaccine Candidate TNX-801 at the Vaccine Congress 2025

Jul 9, 2025, 4:01 PM EDT - 6 months ago

Tonix Pharmaceuticals Announces On-line Publication of Phase 3 RESILIENT Trial Results of TNX-102 SL for Fibromyalgia in the Peer Reviewed Journal, Pain Medicine

Jul 7, 2025, 7:00 AM EDT - 6 months ago

Tonix Pharmaceuticals Announces Oral Presentation on Mpox and Smallpox vaccine candidate TNX-801 at the Vaccine Congress 2025

Jul 2, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Peer-Reviewed Publication in Cancer Cell Journal Highlighting Positive Preclinical Data of mTNX-1700 in Gastric Cancer Animal Models

Jun 30, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Inclusion in the Russell 3000® and Russell 2000® Indexes

Jun 16, 2025, 11:30 AM EDT - 7 months ago

Tonix Pharmaceuticals: Big Risk, Bigger Reward - Initiating With A Buy

Jun 16, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the Annual European Congress of Rheumatology (EULAR) 2025

Jun 13, 2025, 7:30 AM EDT - 7 months ago

Tonix Pharmaceuticals: Is The Recent Sell-Off A Buy Occasion?

Jun 13, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James “Jim” Hunter, to Board of Directors

Jun 10, 2025, 7:00 AM EDT - 7 months ago

Tonix Pharmaceuticals Announces Presentation at the 2025 BIO International Convention

Jun 5, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Poster Presentation at the Annual European Congress of Rheumatology (EULAR) 2025

May 22, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Presentation at the A.G.P. Annual Healthcare Company Showcase

May 21, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces First Patient Dosed in Phase 2 OASIS Study of TNX-102 SL for Reduction of Acute Stress Reaction

May 14, 2025, 7:00 AM EDT - 8 months ago

Tonix Pharmaceuticals Announces Appointment of Joseph Hand, Esq., as General Counsel and Executive Vice President of Operations

May 12, 2025, 4:30 PM EDT - 8 months ago

Tonix Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Highlights

Apr 29, 2025, 9:05 AM EDT - 9 months ago

Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Apr 24, 2025, 7:55 AM EDT - 9 months ago

Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025

Apr 16, 2025, 7:00 AM EDT - 9 months ago

Tonix Pharmaceuticals Announces Oral Presentation and Panel Participation at the World Vaccine Congress Washington 2025

Apr 9, 2025, 7:00 AM EDT - 10 months ago

Tonix Pharmaceuticals and Makana Therapeutics Announce Collaboration Combining Tonix's Anti-CD40L Monoclonal Antibody (TNX-1500) with Makana's Genetically Engineered Organs in Preclinical and Clinical Xenotransplantation Studies

Rungreen Jan. 17 at 1:26 PM

0 · Reply

Ab_23 Jan. 17 at 8:21 AM

$TNXP please tell me there are any good news or numbers

0 · Reply

MoneyGroupLLC Jan. 17 at 7:36 AM

0 · Reply

WarpedHitbox Jan. 17 at 2:52 AM

^@CoralSharkie operating on another level 🧠❄️ Cold vision, real substance. Not following yet? That’s on you. Free game, unreal value. 🐐 > Also watching >> $TNXP $GOVX $IXHL $USAR .

0 · Reply

Biostock Jan. 17 at 2:32 AM

$TNXP When $25.6 billion per share? The epitome of utter capital destruction.

1 · Reply

SouljaOfYah Jan. 17 at 2:18 AM

$TNXP only a fool would think of selling what they have now…. Patience pays

0 · Reply

crazysnake Jan. 17 at 1:56 AM

$TNXP

0 · Reply

Moemazon Jan. 17 at 1:47 AM

$TNXP imagine if any of those crazy targets from before August 15, 2025 actually come to fruition this year.

0 · Reply

crazysnake Jan. 16 at 11:34 PM

$TNXP looks like we are all too poor to subscribe to iqvia ,bloomberg terminal lol who got those numbers?

0 · Reply

C4Trading Jan. 16 at 10:01 PM

$TNXP Long weekend, should be interesting on Tuesday.

1 · Reply

Itinerant Jan. 16 at 9:33 PM

$TNXP Maybe this is the beginning of what we know is coming. I am fully positioned for it, thanks to this Board.

1 · Reply

CIOBRAN Jan. 16 at 8:42 PM

$TNXP GOOD RESULTS, NEWS AND HIGHER VOLUMES ARE NEEDED, THEN $100 IS REACHABLE, FOR THE MOMENT IT IS BETTER TO WAIT FOR FAIRLY GOOD NEWS AND RISE AT LEAST TO $28/30

0 · Reply

ByBi Jan. 16 at 8:32 PM

$TNXP Also, wash sale rule is coming to an end for most.

0 · Reply

ByBi Jan. 16 at 8:24 PM

$TNXP There are over 250k shares that don't appear on the lit so far today, on a 350k shares registered trades. Let that sink in 🤷🏼‍♂️

3 · Reply

JustAguysOpinion Jan. 16 at 8:21 PM

$TNXP Near 2.5m shorted. Look at yearly, 3 and monthly. I take the low turnover as bulls not selling and liquidity drying up. News or a small buy back by tonix can really move this if we just as a collective hold and buy. By now most of us have more than 1k my guess. Not financial just a opinion.

1 · Reply

Supplement Jan. 16 at 8:20 PM

$TNXP Above $150 by summer

3 · Reply

jeni1988 Jan. 16 at 8:19 PM

$TNXP In January 2026, the company announced it would present at two investor conferences and completed a $20.0 million registered direct offering. They also announced program updates for a potential Lyme disease preventative treatment and the licensing of TNX-4900 for chronic neuropathic pain.

0 · Reply

Scalpingstocks Jan. 16 at 8:17 PM

$TNXP as stated yesterday 15.70s support and may hit. Reloaded below $16 now you can have few of my shares 17.20s lol. Screw Seth, we do our own thing when it comes trading a huge pile of shit like $

0 · Reply

Fng4noob Jan. 16 at 8:12 PM

$TNXP another week of loses for the shorts. Time to move on, nothing happening here.💎💎💎

0 · Reply

Ab_23 Jan. 16 at 8:07 PM

$TNXP now sentiment is extremely bullish? Why

1 · Reply

JuggernautRaider Jan. 16 at 8:05 PM

$NUVB I would recommend Symphony demand data instead of IQVIA but confirm their capture rate. But the data is very expensive - Symphony usually charges half of what IQVIA does. You should just buy more shares if you believe 🏦 I may ask Symphony for an estimate on Tonmya demand for $TNXP soon and see what they’re capturing… although will likely get it for free from other sources 💪 Also an FYI for $MIST and $KALV who want to track their recent approvals trends here in the USA 🇺🇸

1 · Reply

Supplement Jan. 16 at 7:54 PM

$TNXP

0 · Reply

Market Cap	193.55M
Revenue (ttm)	10.09M
Net Income (ttm)	-130.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-1,288.80%
Debt to Equity Ratio	0.00

Volume	500,100
Avg Vol	632,620
Day's Range	N/A - N/A
Shares Out	12.17M
Stochastic %K	93%
Beta	1.78
Analysts	Strong Sell
Price Target	$67.00